Skip to main content
Clinical Trials/NCT00897143
NCT00897143
Withdrawn
Not Applicable

Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens

Case Comprehensive Cancer Center1 site in 1 countryJune 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
Case Comprehensive Cancer Center
Locations
1
Primary Endpoint
Isolation and identification of lung cancer precursor cells in malignant pleural effusion specimens
Status
Withdrawn
Last Updated
10 years ago

Overview

Brief Summary

RATIONALE: Studying samples of pleural fluid in the laboratory from patients with lung cancer may help doctors identify early lung cancer cells. It may also help the study of lung cancer in the future.

PURPOSE: This laboratory study is looking at malignant pleural effusion samples from patients with primary lung cancer to see if early lung cancer cells can be identified.

Detailed Description

OBJECTIVES: * Isolate and identify lung cancer precursor cells in discarded pleural fluid specimens obtained during routine thoracentesis procedures for the diagnosis and treatment of malignant pleural effusions. OUTLINE: Malignant pleural effusion specimens obtained from the Pathology Department at the University Hospitals of Cleveland are analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin. The isolated cells are then stained with fluorescent DNA binding dye, Hoechst 33342, and other markers (i.e., CD133, CD24/CD44) and sorted by flow cytometry into progenitor and nonprogenitor subpopulations. The sorted subpopulations are separated and examined functionally by in vitro and in vivo studies. Sphere culture studies are also performed on the sorted subpopulations. The specimens may also be utilized for transcriptional profiling studies, RNAi studies, and for the establishment of long-term cultures and cell lines. DNA is also isolated and stored from tumor and nonepithelial normal cell compartments for future genetic studies on known and unidentified genetic abnormalities contributing to the development of lung cancer, such as EGFR, ErbB2, K-ras, and p53 mutational status.

Registry
clinicaltrials.gov
Start Date
June 2007
End Date
TBD
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Isolation and identification of lung cancer precursor cells in malignant pleural effusion specimens

Study Sites (1)

Loading locations...

Similar Trials